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ABSTRACT
Aim: To determine the time needed to provide clinical pharmacy
services to individual patient episodes for medical and surgical
patients and the effect of patient presentation and complexity
on the clinical pharmacy workload.
Method: During a 5-month period in 2006 at two general
hospitals, pharmacists recorded a defined range of activities
that they provided for patients, including the actual times
required for these tasks. A customised database linked to the
two hospitals’ patient administration systems stored the data
according to the specific patient episode number. The influence
of patient presentation and complexity on the clinical pharmacy
activities provided was also examined.
Results: The average time required by pharmacists to undertake
a medication history interview and medication reconciliation was
9.6 (SD 4.9) minutes. Interventions required 5.7 (SD 4.6) minutes,
clinical review of the medical record 5.5 (SD 4.0) minutes and
medication order review 3.5 (SD 2.0) minutes. For all of these
activities, the time required for medical patients was greater than
for surgical patients and greater for ‘complicated’ patients. The
average time required to perform all clinical pharmacy activities
for 1071 completed patient episodes was 14.4 (SD 10.9) minutes
and was greater for medical and ‘complicated’ patients.
Conclusion: The time needed to provide clinical pharmacy
services was affected by whether the patients were medical or
surgical. The existence of comorbidities or complications affected
these times. The times required to perform clinical pharmacy
activities may not be consistent with recently proposed staff ratios
for the provision of a basic clinical pharmacy service.
J Pharm Pract Res 2008; 38: 126-31.
INTRODUCTION
The range and prevalence of activities that comprise clinical
pharmacy services in Australian hospitals has been reported
previously, along with the extent to which hospitals offer these
services.1-4 However, none of these reports specify the
resources consumed by pharmacy departments in providing
these services. Early reports of clinical pharmacy services in
Australia provided some indication of the resources needed
to provide these services per occupied bed.5,6 Subsequent
studies demonstrated more detailed workload reporting,
although the surveys indicated that the nature of documentation
of clinical pharmacy services was not uniform.7-9 One national
survey of documentation practices showed that no pharmacy
service reported on the time spent providing clinical pharmacy
services to individual patient episodes.9
Recording the time needed to provide clinical pharmacy
services at the individual patient level would allow the effect
of patient complexity on the clinical pharmacy workload to
be determined. This could help with service planning, inform
the PharmGroup analysis of pharmacy episodes of care, and
help manage the Australian Health Ministers’ requirement to
provide pharmaceutical review for inpatients.10,11
We have previously described recording tools to measure
the time required to provide components of clinical pharmacy
services.12 The tools successfully recorded the times to
conduct medication reconciliation as well as other routine
medication monitoring activities and pharmaceutical
interventions. Through the use of these tools, the aim of this
study was to determine the time needed to provide clinical
pharmacy services to individual patient episodes for medical
and surgical patients and the effect of patient presentation
and complexity on the clinical pharmacy workload.
METHOD
The study was conducted at two Melbourne hospitals, the 300-
bed The Northern Hospital, and the 323-bed Western Hospital,
over five months from May to September 2006. The Human
Research and Ethics Committees of Northern Health,
Melbourne Health and Deakin University gave approval for
the study. Study participants were overnight patients discharged
from the medical and surgical wards at The Northern Hospital
and patients discharged from the general medical and surgical
units at Western Hospital. The pattern of clinical pharmacist
activity at the two hospitals was confirmed by direct observation,
similar to that previously reported in other Australian hospitals.13
At The Northern Hospital the medical and surgical wards
(158 beds) were serviced by 4.5 full-time equivalent
pharmacists (average 35 beds/pharmacist). Pharmacists ranged
in experience from newly registered to more than 20 years post-
registration. At the Western Hospital the medical and surgical
units (275 beds) were serviced by 7 full-time equivalent
pharmacists (average 39 beds/pharmacist). Pharmacists ranged
in experience from newly registered to 12 years post-
registration. The participating pharmacists completed the
designated workload documentation each weekday for as many
patients as possible in the high turnover environments of the
two hospitals. No eligible patients were excluded.
Pharmacists at both sites recorded the medication history
interview and medication reconciliation on identical
Pharmaceutical Clinical Pathway (PCP) forms using the tools
previously described.12 Clinical Activity Data Sheets (CADS)
were used at the two hospitals to record clinical activities
such as medication chart review, clinical review, adverse drug
reaction management, therapeutic drug monitoring and
provision of drug information. Each patient intervention was
recorded in the Riskman adverse incident monitoring system.
The recording tools were used as previously, with one
modification to the PCP form—the pharmacists recorded the
time to complete all details on page 1 of the form in a designated
section.12 This included the time to confirm allergy status,
medication history, usual medication administration
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Figure 1. Method of allocating clinical pharmacy activity records to
the patient episode number (PAS = patient administration system)
Figure 2. Interfacing software linking the database and the two patient
administration systems (PAS) allows linking of pharmacy activity data
with patient episode data from the PAS
arrangements and the current location of patients’ own
medicines. Data recorded on page 2 of the PCP form was
not used as we previously found that this information was not
recorded consistently.12 The time needed to complete the PCP
form was also recorded and the completed form was filed in
the medical notes. On the CADS, the pharmacists recorded
the occurrence and date of when they performed each of the
activities. Every one week in four, the time required to perform
each activity on the CADS and the time required for each
intervention entered into Riskman was recorded. Prior to each
of these ‘time sampling’ intervals, a training session was
provided to the participating pharmacists to reinforce the need
to record times, as well as the methods of recording.
Completing the PCP form and recording interventions in
Riskman represented routine practice at both hospitals. The
extra work incurred by participating pharmacists was the use
of the CADS to record the described clinical activities and to
record times to perform the activities measured by the study.
At both hospitals, eligible patients were identified from a list
generated by a clerk from the Health Information Services
Department. The clerk retrieved PCP forms detected from
patients’ medical records and provided a copy to the researchers.
The completed CADS were provided to the researchers by the
pharmacists as each inpatient was discharged from hospital.
Finally, the researchers extracted records of pharmacists’
interventions from Riskman. For each type of record, patients
were identifiable only by their medical record number.
A customised database was developed to record each
activity undertaken on behalf of each patient. Specifically
developed software, integrated with the customised database,
allowed interrogation of each hospital’s patient administration
system and resulted in identification of the unique patient
episode number associated with each patient’s admission. A
clerk entered all patient data into the database, attributing all
clinical pharmacy activity data associated with each patient’s
episode to that specific episode number (Figure 1). The process
allowed the entry to the database of different patient records
at different times, as these records became available. The link
to each patient administration system also enabled the
extraction of patient data relating to that episode, such as length
of stay and the patient’s assigned diagnosis-related group
classification (Figure 2).
diseases within a major disease classification can be of a medical,
surgical or other nature, where the latter refers to diagnostic
procedures such as endoscopy or telemetry.14 Finally, each
disease has a specific diagnosis-related group classification,
which can exist in a ‘complicated’ form (with the existence of
comorbidities or complications) or in an ‘uncomplicated’ form.14
Extraction of the diagnosis-related group classification
allowed the identification of the nature of patient presentation
as medical, surgical or other. It also allowed identification of
the major disease classification associated with each diagnosis-
related group classification.For each patient it was possible to
indicate each episode as complicated (presence of severe or
catastrophic comorbidities or complications) or uncomplicated.
Reports extracted from the customised database detailed
for each record type (PCP forms, CADS records, intervention
extracts), the activities linked to each unique patient episode
number. The researchers then linked the data for each unique
patient episode number together, to produce a record of total
clinical pharmacy activities performed for each patient episode.
This enabled the analysis of patient episodes for the effects of
patient type, major disease classification and patient complexity
on workload. It also enabled the analysis of all component
activities of the completed patient episodes.
The results represent an analysis of the clinical activities
performed by pharmacists during those intervals where they
recorded the time needed to perform clinical activities (i.e. time
sampling intervals). The results include those for the aggregate
of activities comprising completed patient episodes, where all
recorded activities took place within the time sampling intervals.
RESULTS
Over the five months of the study, there were 3701 eligible
patient separations (patients discharged) from the medical and
surgical wards at The Northern Hospital and 3920 eligible
patient separations from the Western Hospital. The number of
patients for whom there was a record of clinical pharmacy
activity performed was 2210 at The Northern Hospital and
2415 at the Western Hospital.
Medical record number input to database
Pharmacist activity record
(Pharmaceutical Clinical Pathway 
form or Clinical Activity Data Sheets 
Via interfacing software, PAS 
identifies one or more patient 
episodes (with dates) associated with 
that medical record number.
Clerk selects patient 
episode number according 
to date of patient activity 
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Pharmacist activity 
recorded in database is 
linked to patient episode 
number.
The disease classification structure used to assign the
diagnosis-related group to each patient episode was the
Australian refined diagnosis-related group structure.14 Within
this structure, diseases affecting a particular body system have
a designated major disease classification (MDC), e.g. MDC
01 is diseases and disorders of the nervous system. Different
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process
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Pharmacists recorded the time to conduct the medication
history interview and medication reconciliation on the PCP
form on 2605 occasions. During time sampling intervals, the
numbers of activities with times recorded on the CADS for
the component activities were: medication order review 2603,
clinical review 1330, adverse drug reaction management 9,
therapeutic drug monitoring 190 and provision of drug
information 387. Pharmacists recorded the times needed for
interventions to treatment on 575 occasions during time
sampling intervals. There were 1071 completed patient
episodes where all of the recorded activities took place within
the time sampling intervals.
An analysis of the times required to conduct the
medication interview and medication reconciliation is shown
in Tables 1 and 2. For all 2605 observations, the mean time
required was 9.6 (SD 4.9) minutes. From the diagnosis-related
group classifications, medical patients required a mean time
of 10.2 (SD 4.8) minutes and this was significantly more than
the mean time of 8.2 (SD 4.9) minutes required for surgical
patients (p < 0.0001). For ‘complicated’ patients the mean
time was 10.5 (SD 4.9) minutes, significantly greater than the
mean time for uncomplicated patients, 8.9 (SD 4.7) minutes
(p < 0.0001).
The mean time for pharmacists’ interventions in all the
patients was 5.7 (SD 4.6) minutes. In medical patients, the
mean time for an intervention was 6.1 (SD 5.1) minutes and
this was significantly greater than for surgical patients, 4.6
(SD 3.1) minutes (p = 0.0003). In complicated patients, the
mean time for an intervention was 6.2 (SD 5.2) minutes,
significantly greater than for uncomplicated patients, 5.2 (SD
3.7) minutes (p = 0.0089).
On the CADS for medication order review and clinical
review, longer activity times were required for medical patients
compared to surgical patients (Table 1) and for complicated
patients compared to uncomplicated patients (Table 2). For
other activities recorded on the CADS during the time sampling
intervals, adverse drug reaction management required a mean
of 6.0 (SD 5.8) minutes, therapeutic drug monitoring required
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a mean of 2.8 (SD 2.0) minutes and provision of drug
information required a mean of 3.8 (SD 3.1) minutes. There
was no difference between medical and surgical patients, or
between complicated and uncomplicated patients, for any of
these activities.
The mean time to conduct all activities comprising a
completed patient episode for all patients was 14.4 (SD 10.9)
minutes. The mean time to conduct all activities comprising a
completed patient episode for medical patients was
significantly greater than that for surgical patients (15.8 SD
11.1 minutes vs 11.0 SD 9.1 minutes; p < 0.0001). In
complicated patients, the mean time was 17.4 (SD 12.0)
minutes, significantly greater than for uncomplicated patients,
12.6 (SD 9.6) minutes (p < 0.0001). For episodes with the
‘other’ diagnosis-related group classification (n = 97), the
mean time to conduct all activities (15.7 SD 11.8 minutes)
was greater than for surgical patients (p = 0.0002). While
the ‘other’ diagnosis-related group category applies largely
to diagnostic and endoscopic procedures, the completed
patient episodes in this study had an average length of stay of
4.3 (SD 3.2) days. Forty patients received diagnosis-related
group classifications relating to gastroscopy for major disease
or complex gastroscopy and a further ten patients received
an invasive cardiac procedure following myocardial infarction.
The completed patient episodes according to their
assigned major disease classification, where the number of
episodes comprising each group was around 100 or more
are shown in Table 3. It ranks the major disease classifications
in order of the decreasing duration required to provide clinical
pharmacy services per episode. Diseases of the circulatory
system required the greatest amount of time while diseases
of the hepatobiliary systems required the least. There was a
difference of more than 50% in the amount of pharmacist
time required for these two forms of patient presentation. The
time required for complicated and uncomplicated diagnosis-
related group presentations, where there were around ten or
more episodes in each sample is also shown in Table 3. Within
each pair, the ‘complex’ presentation required the most time.
The average time needed to provide clinical pharmacy services
for the pooled medical patients in this subset of data was
19.7 (SD 13.6) minutes; the pooled data for surgical patients
was 12.7 (SD 9.2) minutes (p = 0.0008). For complicated
patients (diagnosis-related group description includes the term
‘with catastrophic or severe comorbidities or complications’)
the mean time was 20.0 (SD 13.6) minutes compared to 14.9
(SD 11.1) for uncomplicated patients (diagnosis-related group
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description includes the term ‘without catastrophic or severe
comorbidities or complications) (p = 0.0087) (Table 3). Table
4 shows times for completed episode totals, further analysed
according to diagnosis-related group complexity within patient
types and ranked according to the times required to provide
clinical pharmacy services to these groups of patients.
DISCUSSION
The results of this study represent activities recorded by
pharmacists during the time sampling intervals—blocks of five
working days once every four weeks over a five-month period.
As the activities were discrete and complete at the time of
recording, it was expected that they would be reflective of all
the activities conducted over the duration of the study. However,
episodes that included data recorded outside the five day time
sampling intervals were excluded from analysis and these would
have included longer episodes extending beyond the sampling
intervals. The episode totals reported thereby represent a subset
of episodes with shorter lengths of stay.
A 2006 analysis of the Australian pharmacy workforce,
attempted to forecast the clinical pharmacist workforce
needed to meet the requirements of the Australian Health
Ministers’ recommendation for the provision of pharmaceutical
review for inpatients.15 This included estimates of the beds to
pharmacist ratios for the provision of ‘comprehensive’ clinical
pharmacy services and ‘basic’ clinical pharmacy services.
A ‘comprehensive’ clinical pharmacy service was
characterised as the Society of Hospital Pharmacists of
Australia’s definition of a ‘basic’ clinical pharmacy service
plus the additional services to achieve Principles 6, 8, 9 and
10 of the Australian Pharmaceutical Advisory Council’s
guidelines to achieve continuity in medication management.16,17
A ‘basic’ clinical pharmacy service was defined to comprise
an accurate medication history interview, assessment of
current medication management and the provision of medicines
information to patients.16 The recommended beds to
pharmacist ratio was 55 beds for medical patients and 62
beds for surgical patients, in an eight-hour day. This represents
average daily time allocations per patient of 8.7 and 7.7
minutes for medical and surgical patients, respectively.
In this present study, the time required to conduct a
medication history interview and medication reconciliation on
admission was around 10 minutes. The interventions to
treatment and clinical review of the medical record or
pathophysiology results both required about 5.5 minutes and
medical order review required about 3.5 minutes. Medical
patients and those with comorbidities and complications
compounding their treatment were predictors of longer times
to conduct these activities in all cases. These findings can be
applied to the recently proposed beds to pharmacist ratios
for the provision of ‘basic’ clinical pharmacy services.15
A pharmacist with a daily case load of 55 medical beds to
which they are providing a ‘basic’ clinical pharmacy service,
could expect ten new patients requiring admission interviews
as well as interventions to correct medication admission errors
and for other therapeutic recommendations. Approximately ten
patients would need provision of medicines information on
discharge and the remaining 45 patients would require ongoing
medication management assessment. From the present study
the activity times for medical patients indicates that a pharmacist
could potentially achieve this in an eight-hour day. A similar
conclusion could also apply to the recommended bed ratio for
a ‘basic’ clinical pharmacy service to surgical beds.
However, higher patient turnovers and other factors such
as the elements of travelling and unproductive time, would
affect the ability to achieve these ratios. These factors, along
with the assistance to prescribers with the Pharmaceutical
Benefits Scheme, and involvement in clinical education, reduce
the likelihood of achieving the proposed bed ratios.18,19
Furthermore, a pharmacist’s duty of care requires the pursuit
of medication safety and therapeutic goals and this may be
compromised by restricting the level of service to a ‘basic’
level for all patients. The data from the present study can
thereby provide only qualified support for the proposed ratios
for the provision of basic clinical pharmacy services to medical
and surgical beds.15
In 1993, Howitt measured hospital pharmacy services
provided to individual patient episodes of care. The provision
of services was not quantified in units of time but expressed
as clinical pharmacy workload in terms of the number of
activities provided, multiplied by a ‘relative value unit’ for each
type of service.20 Patient episodes fell into four groups that
were classified according to the required clinical pharmacy
input. The identified groupings were in ascending order of the
input required as follows:20
1. those with a shorter length of stay (investigative or minor
surgical procedure);
2. those with a general medical disorder requiring intermittent
hospitalisation;
3. those requiring complex medical care (diabetes, receiving
chemotherapy); and
4. those requiring intensive care or undergoing significant
surgical or medical care.
Caution is required when comparing data from the present
study with Howitt’s report as different types of patient episodes
were analysed. Howitt included day-admitted patients,
intensive care patients, patients undergoing chemotherapy and
patients receiving organ transplants. The present study involved
overnight patients under the care of general medical and
surgical units. Also in the present study, the subset of patients
included had relatively short lengths of stay whereas Howitt
included all completed episodes for which data were available.
Notwithstanding the above differences, comparison shows
that the pharmaceutical input required for completed patient
episodes in our study was in the following ascending order
(Table 4):
1. surgical patients without a diagnosis-related group
comorbidity or complexity;
2. medical patients without a diagnosis-related group
comorbidity or complexity, patients undergoing less
complicated investigations and surgical patients with a
diagnosis-related group comorbidity or complexity; and
3. medical patients with a diagnosis-related group
comorbidity or complexity and patients undergoing
relatively complex investigational procedures.
There is a degree of similarity between these classifications
and those reported by Howitt. In both studies, uncomplicated
surgical patients required the least input and complex medical
patients the most, and uncomplicated medical patients and
complex surgical patients required intermediate input.
This study to our knowledge is the first published work
that attributes the time to perform clinical pharmacy activities
for individual patients. It has allowed the determination of
average times needed to perform these activities and the
identification of factors (type of patient presentation – medical
or surgical – the major disease classification and the complexity
of the individual diagnosis-related group presentation) that
influenced these average times. Our study has provided new
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information about the influence of comorbidities and
complications accompanying a patient’s presentation. The
diagnosis-related group classification is not assigned until well
after discharge and thereby cannot influence in advance the
activities to be performed. It is thereby apparent that factors
that determine the eventual diagnosis-related group
classification also prospectively influence medication
management activities by the pharmacist.
The study also provides information about the influence
of the above factors on the total time commitments by
pharmacists for completed patient episodes. However, this
information only relates to patients with relatively short lengths
of stay. Nevertheless, the influences on time commitments on
the patient subset in our study confirmed the patterns indicated
in an earlier report.20 The presentation of the complete data
collected in our study involves a statistical imputation of times
associated with activities recorded during non-time-sampling
intervals and is forthcoming. This will provide information
about clinical pharmacy commitments for longer patient
episodes.
A limitation of the study was that of the different levels
of experience of pharmacists providing clinical services to
patients. Pharmacists ranged in experience from newly
qualified to those with many years of experience in hospital
practice. Conversely, this can also be interpreted as a strength
of the study as it reflects the ‘real world’ environment. The
managers at the pharmacy departments deployed pharmacists
to clinical areas according to operational requirements; the
researchers did not attempt to influence the alignment of
pharmacists’ experience with particular clinical areas.
However, all participating pharmacists used the same
recording tools and received the same training and education
in their use. Another limitation was the use of a self-reporting
method to record the times required by pharmacists to perform
each activity, rather than using independent observers. Using
independent observers would have reduced the amount of
data collected and may have also influenced the times
recorded.18 Rather, we provided a training session to
pharmacists prior to each time sampling interval to ensure
consistent recording of the time taken to perform the various
activities. Finally, the study method clearly confines our results
to clinical pharmacy activities for patients treated in the
medical and surgical wards of general hospitals. Our study
did not include emergency or intensive care patients, patients
undergoing chemotherapy or patients undergoing highly
specialised treatment, such as organ transplantations.
In conclusion, the time needed to provide clinical
pharmacy services for individual patient episodes for medical
and surgical patients was successfully quantified. Further
analysis of data collected will allow determination of total
clinical pharmacy workload for longer patient episodes,
providing a more complete assessment of the workload
commitments of different patient presentations in medical and
surgical wards.
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